253 related articles for article (PubMed ID: 16838163)
1. Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Björkholm M; Celsing F; Johansson E;
Ann Hematol; 2006 Oct; 85(10):731-3. PubMed ID: 16838163
[No Abstract] [Full Text] [Related]
2. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
Bron D; Vandenheule B; Stryckmans P
Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298
[No Abstract] [Full Text] [Related]
3. Hematologic malignancies: non-Hodgkin's lymphomas.
DeVita VT
Hosp Pract (Off Ed); 1986 Sep; 21(9):103-18. PubMed ID: 2427535
[No Abstract] [Full Text] [Related]
4. [Chemotherapy for non-Hodgkin's lymphoma].
Kuraishi Y; Usui N; Dobashi N
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2210-6. PubMed ID: 9881077
[TBL] [Abstract][Full Text] [Related]
5. ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher RI; Young RC; Longo D; DeVita VT
Semin Oncol; 1985 Mar; 12(1 Suppl 2):29-32. PubMed ID: 2579441
[TBL] [Abstract][Full Text] [Related]
6. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
7. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
8. A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.
Angrilli F; Pennese E; Di Marzio A; Liberatore E; Di Lorenzo R; Fioritoni G
Haematologica; 2002 Nov; 87(11):1227-9. PubMed ID: 12414356
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?
Gaynor ER; Fisher RI
Oncology (Williston Park); 1995 Dec; 9(12):1273-9; discussion 1283-4. PubMed ID: 8771102
[TBL] [Abstract][Full Text] [Related]
10. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
11. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
12. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
13. Non-hodgkins lymphoma.
Mead G; Woodcock J; Young C
Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
[No Abstract] [Full Text] [Related]
14. [Long-term follow up of aggressive lymphoma patients treated with CAMBO-VIP--clinical significance of a residual mass after otherwise successful chemotherapy].
Okamoto M
Rinsho Ketsueki; 1998 Feb; 39(2):111-2. PubMed ID: 9545814
[No Abstract] [Full Text] [Related]
15. Results of three polychemotherapy programs in non-Hodgkin's lymphomas.
Konopka L; Pawelski S
J Chemother; 1989 Jul; 1(4 Suppl):1259-62. PubMed ID: 16312857
[No Abstract] [Full Text] [Related]
16. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
17. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
18. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
[TBL] [Abstract][Full Text] [Related]
20. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
Sampi K; Honda T; Hattori M
Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
